Standard Operating Procedures (SOPs) are critical for the operation of any business, particularly in regulated industries like pharmaceuticals where precision, safety, and compliance with regulatory requirements are paramount. For a pharmaceutical company, SOPs for observational studies and clinical trials should be separated due to the distinct nature and objectives of each type of study. Here are the main reasons:
[1] Different objectives: Clinical trials are experiments designed to evaluate the safety and efficacy of a new drug or intervention. On the other hand, observational studies are non-interventional; they involve the collection of data without altering the patients’ usual treatment or environment, aiming to observe and analyse patterns, effects, or outcomes.
[2] Regulatory requirements: Clinical trials are highly regulated, with strict GxP requirements from bodies like the FDA or EMA. Observational studies, while still regulated, do not fall under the same stringent GxP requirements. Having separate SOPs ensures compliance with the correct set of regulations for each type of study.
[3] Study design and conduct: The design and conduct of clinical trials and observational studies are significantly different. For instance, clinical trials are generally randomized, controlled, and blinded studies. In contrast, observational studies may involve case-control studies, cohort studies, or cross-sectional studies. Different SOPs can specify the appropriate designs, methods and checks for data collection, storage, and analysis in each case.
[4] Patient consent and confidentiality: In clinical trials, patients provide informed consent for the specific interventional treatment they will receive. In observational studies, while consent is still required, it’s often related to access and use of their medical data rather than a specific treatment. Thus, separate SOPs can address these differing requirements.
[5] Risk Management: Risks and safety considerations also vary between clinical trials and observational studies. The risks of clinical trials often relate to the new drug or intervention being tested, while observational studies’ risks typically concern data protection and patient privacy.
[6] Reporting Results: Different types of studies may also have different reporting requirements, including timelines, formats, and recipients of the information (e.g., regulatory authorities, ethics committees, sponsors).
By having separate SOPs, companies ensure that all these aspects are appropriately addressed, leading to better quality, more ethical research, and improved compliance with regulatory requirements. It also helps in training and guiding staff effectively in their roles for different studies.
Share this story...
Real World Evidence (RWE) 101 – Is ‘Retrospective Data’ the Same as ‘Secondary Use of Existing Data’?
RWE 101 - Is 'Retrospective Data' the Same as 'Secondary Use of Existing Data'? Retrospective data generally refers to data that has already been collected for another purpose [...]
Real World Evidence (RWE) 101 – EHDS and GDPR – How does GDPR support the secondary use of existing health data for the purposes of scientific research?
RWE 101 - EHDS and GDPR - How does GDPR support the secondary use of existing health data for the purposes of scientific research? The GDPR (General Data [...]
Real World Evidence (RWE) 101 – Federated Clinical Data
RWE 101 - Federated Clinical Data Federated clinical data refers to clinical data that is distributed across multiple organizations or entities, such as hospitals, clinics, research institutions, [...]
Real World Evidence (RWE) 101 – The European Health Data Space (EHDS)
RWE 101 - The European Health Data Space (EHDS) The European Health Data Space (EHDS) is a proposed initiative by the European Union to create a secure and [...]
Real World Evidence (RWE) 101 – The Impact of the EMAs Data Quality Framework on RWE
RWE 101 - The Impact of the EMAs Data Quality Framework on RWE The EMA (European Medicines Agency) data quality framework provides a set of guidelines and principles [...]
Real World Evidence (RWE) 101 – DARWIN-EU
RWE 101 - DARWIN-EU DARWIN-EU is a project that aims to establish a sustainable platform for generating and using real-world evidence (RWE) to support decision-making in healthcare [...]







